Scientist works to interrupt early changes resulting in diabetic vision loss

March 12, 2004

Years before an overgrowth of vessels destroys the sight of diabetics, vital nerve cells in the retina begin to die.

The dying cells have a characteristic appearance. "They are often adjacent to cells that appear normal; it's kind of a civilized death," says Dr. Sylvia Smith, retinal cell biologist at the Medical College of Georgia, as she looks at a microscopic image of the dying cells.

While the specific initiating event that leads to late-onset vascular changes is not certain, the death of these neurons may contribute to the complex cascade of events that disrupts the beautifully organized retina over years; eventually, this back portion of the eye begins to grow new blood vessels, presumably in an attempt to rescue dying cells by providing more blood and oxygen.

Unfortunately, the growth of new vessels obstructs vision. They can leak and cause scarring in a condition called diabetic retinopathy, the number-one cause of vision loss in working-age adults.

Dr. Smith recently received a $1 million, four-year grant from the National Eye Institute to understand better how these dying ganglion cells live and why the increased glucose levels in diabetics prompt their death.

Better still, she wants to know if drugs called sigma receptor ligands can preserve ganglion cells and stop the destructive blood vessel proliferation that seems to follow.

"We are not studying the vascular problems in this project as they set in after many years of diabetes in humans and animal models. We are interested in the early changes and we have evidence that there are changes in the nerve cells in the retina long before you have these gross blood vessels growing," she says. Problems seem to start with ganglion cells, nerve cells found in the inner part of the retina. "The axons of these cells join to form the optic nerve, which then goes to the brain and delivers a visual image," she says. While the idea that these cells might be affected by diabetes is not new, its acceptance is.

Evidence is mounting that transporters, which carry vital substances into and out of cells, may be affected by high glucose levels in diabetes, Dr. Smith says. Without proper transportation, out-of-place and out-of-control substances such as glutamate, an amino acid plentiful inside ganglion cells where it works as a communicator, can be toxic. "It's all about location and balance," says Dr. Smith. If glutamate accumulates outside of the cell it can over-stimulate the cell by binding to a glutamate receptor. One such receptor, the NMDA receptor, is particularly sensitive to excessive levels of glutamate. Over-stimulation of NMDA receptors allows too much calcium to enter the cells where it triggers formerly dormant cell-death pathways.

"The hypothesis we are testing is does this increase in glucose, this hyperglycemic state that occurs in diabetes, affect the transport of glutamate such that it might subject cells to an excessive level of glutamate, which is toxic?" Dr. Smith says of her studies in diabetic animal models.

The researcher has evidence that transport of folate or folic acid, a vitamin essential to RNA, DNA and ultimately protein synthesis, is disrupted in diabetes as well. A deficiency in folate can precipitate an increase in the level of homocysteine, an excitatory amino acid that, like glutamate, can stimulate the NMDA receptor.

Additionally, high glucose may impair other transporters found on supportive cells such as retinal Muller cells, which help eliminate unnecessary or even harmful substances in and around cells. Muller cells, for example, can take up glutamate and convert it to harmless glutamine, so Dr. Smith also is studying how these cells are affected by high glucose.

While continuing to dissect the process that results in ganglion cell death and the ultimate role that death plays in abnormal blood vessel growth, Dr. Smith already is working to interrupt it.

In an animal model, she is using sigma receptor ligands, compounds not naturally occurring in the body but known for their ability to protect cells and under study for their potential in memory disorders and other diseases. She has preliminary evidence that, at least early on, these ligands can prevent ganglion cell death perhaps by interfering with glutamate's over-stimulation of NMDA receptors.

"These are potent drugs and they seem to have a multitude of neuro-protective functions including inhibiting NMDA activation that sets up this deadly cascade," Dr. Smith says. "So we are testing these sigma receptor ligands to prevent this neuronal death. It may be a little ambitious, but that is what we are doing. If we can get strong evidence that these drugs have a beneficial effect on ganglion cell death, that is an important finding."

She recently submitted for publication findings documenting the dramatic reduction in cell death resulting from the injections of the ligand, Pentazocine. "We have a long way to go, but nevertheless, I think it's quite promising," Dr. Smith says.
-end-


Medical College of Georgia at Augusta University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.